relation to age and differentiation
[1] [2] While this medication has demonstrated significant benefits for glycemic control and weight reduction, it carries a boxed warningthe FDA's most serious safety alertregarding thyroid C-cell tumors observed in animal studies
Curr Pharm Des 20:11261135 Sikiri P, Petek M, Ruman R, Seiwerth S, Grabarevi Z, Rotkvi I, Turkovi B, Jagi V, Mildner B, Duvnjak M, Lang N, Danilovi Z, Cviko A, Kolega M, Sallmani A, Djai S, Bura M, Brki T, Bani M, Dodig M, Cori V, imievi V, Veljaca M, Erceg D, Jeek D, Simuni-Banek L, Skroza N, Buli K, Buljat G, Hanevaki M, Orihova V, Luinger D, Culig J, Separovi J, Marovi A, Mie S, Suchanek E, Matoz W, Perovi D, Gjurain M, Mikulandra S, Dernikovi K, Cuk V, Karakas I (1993) A new gastric juice peptide, BPC
Here we overview the glucose-lowering and weight-reducing effects of incretin-based therapies, discussing the effective and safety use of DPP-4 inhibitors, GLP-1 RAs, and GIP/GLP-1 receptor agonist tripeptide in Japanese individuals with type 2 diabetes